{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:03:34Z","timestamp":1793361814426,"version":"4.5.0"},"reference-count":175,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","nmd-journal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.nmd.2024.104453","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:37:49Z","timestamp":1728002269000},"page":"104453","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["273rd ENMC International workshop: Clinico-Sero-morphological classification of the Antisynthetase syndrome. Amsterdam, The Netherlands, 27-29 October 2023"],"prefix":"10.1016","volume":"45","author":[{"given":"Werner","family":"Stenzel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew L","family":"Mammen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Gallay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Therese","family":"Holzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Kleefeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Benveniste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Allenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Allenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Benveniste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Damoiseaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonye K.","family":"Danoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Diederichsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Fiorentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Gallay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Giannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Therese","family":"Holzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Kleefeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lia","family":"Kolsters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Lundberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew L.","family":"Mammen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Minopulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinna","family":"Preusse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Ruck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jantima","family":"Tanboon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah L.","family":"Tansley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Stenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yurdagul","family":"Uzunhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2024.104453_bib0001","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/qjmed\/77.1.1019","article-title":"Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes","volume":"77","author":"Marguerie","year":"1990","journal-title":"Q J Med"},{"key":"10.1016\/j.nmd.2024.104453_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102951","article-title":"Autoantigenic properties of the aminoacyl tRNA synthetase family in idiopathic inflammatory myopathies","volume":"134","author":"Preger","year":"2023","journal-title":"J Autoimmun"},{"key":"10.1016\/j.nmd.2024.104453_bib0003","article-title":"Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course","volume":"8","author":"Cavagna","year":"2013","journal-title":"J Clin Med"},{"key":"10.1016\/j.nmd.2024.104453_bib0004","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1136\/ard-2022-222686","article-title":"Mass spectrometry-based identification of new anti-Ly and known antisynthetase autoantibodies","volume":"82","author":"Vulsteke","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nmd.2024.104453_bib0005","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1093\/rheumatology\/kez504","article-title":"The myositis clinical phenotype associated with anti-Zo autoantibodies: a case series of nine UK patients","volume":"59","author":"Tansley","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nmd.2024.104453_bib0006","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/rheumatology\/35.4.305","article-title":"Polymyositis-associated overlap syndromes","volume":"35","author":"Venables","year":"1996","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.nmd.2024.104453_bib0007","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nmd.2024.104453_bib0008","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jaut.2007.07.005","article-title":"Species-specific immune responses generated by histidyl-tRNA synthetase immunization are associated with muscle and lung inflammation","volume":"29","author":"Katsumata","year":"2007","journal-title":"J Autoimmun"},{"key":"10.1016\/j.nmd.2024.104453_bib0009","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1002\/art.22865","article-title":"Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy","volume":"56","author":"Stone","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2024.104453_bib0010","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1007\/s00296-023-05372-9","article-title":"Healthcare utilization and unmet needs of patients with antisynthetase syndrome: an international patient survey","volume":"43","author":"Weiss","year":"2023","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.nmd.2024.104453_bib0011","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.autrev.2012.06.006","article-title":"Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity","volume":"12","author":"Hervier","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.nmd.2024.104453_bib0012","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.autrev.2014.03.004","article-title":"The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome","volume":"13","author":"Lega","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.nmd.2024.104453_bib0013","doi-asserted-by":"crossref","first-page":"e60442","DOI":"10.1371\/journal.pone.0060442","article-title":"Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome","volume":"8","author":"Hamaguchi","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.nmd.2024.104453_bib0014","doi-asserted-by":"crossref","first-page":"e798","DOI":"10.1097\/MD.0000000000000798","article-title":"Myocarditis in Patients With Antisynthetase Syndrome: prevalence, Presentation, and Outcomes","volume":"94","author":"Dieval","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.nmd.2024.104453_bib0015","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1093\/rheumatology\/kead541","article-title":"Myocarditis in anti-synthetase syndrome: clinical features and diagnostic modalities","volume":"63","author":"De Luca","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nmd.2024.104453_bib0016","series-title":"256th ENMC international workshop: Myositis specific and associated autoantibodies (MSA-ab): Amsterdam, The Netherlands, 8-10 October 2021","article-title":"ENMC 256th Workshop Study Group","author":"Damoiseaux","year":"2022"},{"key":"10.1016\/j.nmd.2024.104453_bib0017","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1136\/annrheumdis-2012-201800","article-title":"Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients","volume":"73","author":"Aggarwal","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nmd.2024.104453_bib0018","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1093\/rheumatology\/keab166","article-title":"A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies","volume":"60","author":"Oldroyd","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nmd.2024.104453_bib0019","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.autrev.2005.05.007","article-title":"From ANA to ENA: how to proceed?","volume":"5","author":"Damoiseaux","year":"2006","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.nmd.2024.104453_bib0020","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1136\/annrheumdis-2019-216003","article-title":"Standardisation of myositis-specific antibodies: where are we today?","volume":"80","author":"Mahler","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nmd.2024.104453_bib0021","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1136\/annrheumdis-2017-212915","article-title":"Detection of myositis-specific antibodies","volume":"78","author":"Vulsteke","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nmd.2024.104453_bib0022","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jaut.2019.04.001","article-title":"Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients","volume":"101","author":"Betteridge","year":"2019","journal-title":"J Autoimmun"},{"key":"10.1016\/j.nmd.2024.104453_bib0023","doi-asserted-by":"crossref","first-page":"4","DOI":"10.5114\/reum.2020.93505","article-title":"The clinical phenotype associated with antisynthetase autoantibodies","volume":"58","author":"Masiak","year":"2020","journal-title":"Reumatologia"},{"key":"10.1016\/j.nmd.2024.104453_bib0024","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/art.21883","article-title":"Unusually high frequency of autoantibodies to PL-7 associated with milder muscle disease in Japanese patients with polymyositis\/dermatomyositis","volume":"54","author":"Yamasaki","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2024.104453_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103403","article-title":"Autoantibodies against tyrosyl-tRNA synthetase (anti-Ha antibodies)","volume":"22","author":"Yamano","year":"2023","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.nmd.2024.104453_bib0026","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.975939","article-title":"The use of ELISA is comparable to immunoprecipitation in the detection of selected myositis-specific autoantibodies in a European population","volume":"13","author":"Loganathan","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.nmd.2024.104453_bib0027","doi-asserted-by":"crossref","first-page":"e85062","DOI":"10.1371\/journal.pone.0085062","article-title":"The multicenter study of a new assay for simultaneous detection of multiple anti-aminoacyl-tRNA synthetases in myositis and interstitial pneumonia","volume":"9","author":"Nakashima","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.nmd.2024.104453_bib0028","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1093\/rheumatology\/keaa021","article-title":"The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity","volume":"59","author":"Tansley","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nmd.2024.104453_bib0029","doi-asserted-by":"crossref","first-page":"212","DOI":"10.55563\/clinexprheumatol\/3cuc1s","article-title":"Pitfalls in the detection of myositis specific antibodies by lineblot in clinically suspected idiopathic inflammatory myopathy","volume":"38","author":"Piette","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.nmd.2024.104453_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2019.100013","article-title":"Frequencies and clinical associations of myositis-related antibodies in The Netherlands: a one-year survey of all Dutch patients","volume":"2","author":"Platteel","year":"2019","journal-title":"J Transl Autoimmun"},{"key":"10.1016\/j.nmd.2024.104453_bib0031","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1111\/1756-185X.14174","article-title":"Performance of myositis-specific antibodies detected on myositis line immunoassay to diagnose and sub-classify patients with suspected idiopathic inflammatory myopathy, a retrospective records-based review","volume":"24","author":"Beaton","year":"2021","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.nmd.2024.104453_bib0032","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1172\/JCI116493","article-title":"Reaction of anti-OJ autoantibodies with components of the multi-enzyme complex of aminoacyl-tRNA synthetases in addition to isoleucyl-tRNA synthetase","volume":"91","author":"Targoff","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nmd.2024.104453_bib0033","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1183\/13993003.00150-2015","article-title":"An official European Respiratory Society\/American Thoracic Society research statement: interstitial pneumonia with autoimmune features","volume":"46","author":"Fischer","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.nmd.2024.104453_bib0034","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01205-2020","article-title":"Myositis-specific Antibodies Identify A Distinct Interstitial Pneumonia with Autoimmune Features Phenotype","author":"Graham","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.nmd.2024.104453_bib0035","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias","volume":"188","author":"Travis","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.nmd.2024.104453_bib0036","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2214\/AJR.17.18384","article-title":"CT Features of the usual interstitial pneumonia pattern: differentiating connective tissue disease-associated interstitial lung disease from idiopathic pulmonary fibrosis","volume":"210","author":"Chung","year":"2018","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.nmd.2024.104453_bib0037","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1159\/000488358","article-title":"Predictive factors for the long-term deterioration of pulmonary function in interstitial lung disease associated with anti-aminoacyl-tRNA synthetase antibodies","volume":"96","author":"Yamakawa","year":"2018","journal-title":"Respiration"},{"key":"10.1016\/j.nmd.2024.104453_bib0038","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12890-021-01399-5","article-title":"Clinical features of anti-synthetase syndrome associated interstitial lung disease: a retrospective cohort in China","volume":"21","author":"Zhan","year":"2021","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.nmd.2024.104453_bib0039","doi-asserted-by":"crossref","first-page":"3480","DOI":"10.1007\/s00330-021-08411-w","article-title":"Idiopathic inflammatory myopathies: CT characteristics of interstitial lung disease and their association(s) with myositis-specific autoantibodies","volume":"32","author":"Laporte","year":"2022","journal-title":"Eur Radiol"},{"key":"10.1016\/j.nmd.2024.104453_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2021.106697","article-title":"Pulmonary histopathology of interstitial lung disease associated with antisynthetase antibodies","volume":"191","author":"Flashner","year":"2022","journal-title":"Respir Med"},{"key":"10.1016\/j.nmd.2024.104453_bib0041","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.semarthrit.2016.03.011","article-title":"Clinical manifestations and long-term outcome of anti-Jo1 antisynthetase patients in a large cohort of Spanish patients from the GEAS-IIM group","volume":"46","author":"Trallero-Aragu\u00e1s","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.nmd.2024.104453_bib0042","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3899\/jrheum.181141","article-title":"Evolution of pulmonary function in a cohort of patients with interstitial lung disease and positive for antisynthetase antibodies","volume":"47","author":"Gonz\u00e1lez-P\u00e9rez","year":"2020","journal-title":"J Rheumatol"},{"key":"10.1016\/j.nmd.2024.104453_bib0043","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.rmed.2012.01.001","article-title":"Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome","volume":"106","author":"Marie","year":"2012","journal-title":"Respir Med"},{"key":"10.1016\/j.nmd.2024.104453_bib0044","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ejim.2023.06.012","article-title":"Phenotypic Profiles Among 72 Caucasian and Afro-Caribbean Patients with Antisynthetase Syndrome Involving Anti-PL7 or Anti-PL12 Autoantibodies","volume":"115","author":"Abel","year":"2023","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.nmd.2024.104453_bib0045","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3389\/fmed.2020.00363","article-title":"Predictors and mortality of rapidly progressive interstitial lung disease in patients with idiopathic inflammatory myopathy: a series of 474 Patients","volume":"7","author":"Li","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.nmd.2024.104453_bib0046","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13613-018-0433-3","article-title":"Clinical features and outcome of patients with acute respiratory failure revealing anti-synthetase or anti-MDA-5 dermato-pulmonary syndrome: a French multicenter retrospective study","volume":"8","author":"Vuillard","year":"2018","journal-title":"Ann Intensive Care"},{"key":"10.1016\/j.nmd.2024.104453_bib0047","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/1756-185X.14443","article-title":"Two clusters of systemic lupus erythematosus patients with muscle involvement in a Chinese cohort","volume":"26","author":"Zhao","year":"2023","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.nmd.2024.104453_bib0048","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02571-2021","article-title":"Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry","volume":"60","author":"Hambly","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.nmd.2024.104453_bib0049","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003121","article-title":"Interstitial lung disease with and without progressive fibrosing phenotype in patients with idiopathic inflammatory myopathies: data from a large multicentric cohort","volume":"9","author":"Zanatta","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.nmd.2024.104453_bib0050","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.chest.2023.01.031","article-title":"Diagnosis and management of myositis-associated lung disease","volume":"163","author":"Hallowell","year":"2023","journal-title":"Chest"},{"key":"10.1016\/j.nmd.2024.104453_bib0051","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","article-title":"Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline","volume":"198","author":"Raghu","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.nmd.2024.104453_bib0052","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/art.42860","article-title":"2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) guideline for the screening and monitoring of interstitial lung disease in people with systemic autoimmune rheumatic diseases","volume":"76","author":"Johnson","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.nmd.2024.104453_bib0053","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1212\/WNL.0000000000002863","article-title":"Anti-TIF1-\u03b3 antibody and cancer-associated myositis: a clinicohistopathologic study","volume":"87","author":"Hida","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2024.104453_bib0054","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40478-016-0308-5","article-title":"Differential roles of hypoxia and innate immunity in juvenile and adult dermatomyositis","volume":"4","author":"Preu\u00dfe","year":"2016","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.nmd.2024.104453_bib0055","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00401-023-02669-8","article-title":"Complement and MHC patterns can provide the diagnostic framework for inflammatory neuromuscular diseases","volume":"147","author":"Nelke","year":"2024","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.nmd.2024.104453_bib0056","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s40478-014-0154-2","article-title":"Myofiber HLA-DR expression is a distinctive biomarker for antisynthetase-associated myopathy","volume":"2","author":"Aouizerate","year":"2014","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.nmd.2024.104453_bib0057","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000001422","article-title":"Nuclear actin aggregation is a hallmark of anti-synthetase syndrome-induced dysimmune myopathy","author":"Stenzel","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2024.104453_bib0058","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1093\/brain\/awv192","article-title":"Anti-Jo-1 antibody-positive patients show a characteristic necrotizing perifascicular myositis","volume":"138","author":"Mescam-Mancini","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.nmd.2024.104453_bib0059","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/aww125","article-title":"Perifascicular necrosis in anti-synthetase syndrome beyond anti-Jo-1","author":"Uruha","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.nmd.2024.104453_bib0060","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/bpa.12772","article-title":"Sequestosome-1 (p62) expression reveals chaperone-assisted selective autophagy in immune-mediated necrotizing myopathies","volume":"30","author":"Fischer","year":"2020","journal-title":"Brain Pathol"},{"key":"10.1016\/j.nmd.2024.104453_bib0061","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-004552","article-title":"A retrospective cohort study identifying the principal pathological features useful in the diagnosis of inclusion body myositis","volume":"4","author":"Brady","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.nmd.2024.104453_bib0062","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1212\/WNL.0000000000003568","article-title":"Sarcoplasmic MxA expression: a valuable marker of dermatomyositis","volume":"88","author":"Uruha","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2024.104453_bib0063","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/nan.12551","article-title":"Absence of sarcoplasmic myxovirus resistance protein A (MxA) expression in antisynthetase syndrome in a cohort of 194 cases","volume":"45","author":"Inoue","year":"2019","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.nmd.2024.104453_bib0064","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ana.20464","article-title":"Interferon-alpha\/beta-mediated innate immune mechanisms in dermatomyositis","volume":"57","author":"Greenberg","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2024.104453_bib0065","doi-asserted-by":"crossref","first-page":"e1193","DOI":"10.1212\/WNL.0000000000008128","article-title":"Identification of distinctive interferon gene signatures in different types of myositis","volume":"93","author":"Pinal-Fernandez","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2024.104453_bib0066","first-page":"kead668","article-title":"Comment on: rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T cells after failure of several B-cell depleting antibodies","author":"Ruffer","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nmd.2024.104453_bib0067","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1136\/jnnp.68.4.472","article-title":"Myopathy with anti-Jo-1 antibodies: pathology in perimysium and neighbouring muscle fibres","volume":"68","author":"Mozaffar","year":"2000","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.nmd.2024.104453_bib0068","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.1212\/NXI.0000000000000434","article-title":"Immune myopathies with perimysial pathology: clinical and laboratory features","volume":"5","author":"Bucelli","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.nmd.2024.104453_bib0069","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1212\/WNL.0000000000011269","article-title":"Pathologic Features of Anti-Mi-2 Dermatomyositis","volume":"96","author":"Tanboon","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2024.104453_bib0070","doi-asserted-by":"crossref","first-page":"e13155","DOI":"10.1111\/bpa.13155","article-title":"Muscle pathology of antisynthetase syndrome according to antibody subtypes","volume":"33","author":"Tanboon","year":"2023","journal-title":"Brain Pathol"},{"key":"10.1016\/j.nmd.2024.104453_bib0071","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00401-022-02438-z","article-title":"Skeletal muscle provides the immunological micro-milieu for specific plasma cells in anti-synthetase syndrome-associated myositis","volume":"144","author":"Preu\u00dfe","year":"2022","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.nmd.2024.104453_bib0072","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1093\/rheumatology\/keac569","article-title":"A new autoantibody to valyl transfer RNA synthetase associated with anti-synthetase syndrome","volume":"62","author":"Sasai","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nmd.2024.104453_bib0073","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/rheumatology\/keh404","article-title":"Functional outcome and quality of life in adult patients with idiopathic inflammatory myositis","volume":"44","author":"Ponyi","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nmd.2024.104453_bib0074","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1001\/jamaneurol.2018.2598","article-title":"Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies","volume":"75","author":"Mariampillai","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.nmd.2024.104453_bib0075","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1136\/ard.2007.078907","article-title":"Subluxing arthropathy: an unusual manifestation of the antisynthetase syndrome","volume":"68","author":"Meyer","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nmd.2024.104453_bib0076","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1002\/art.1780331106","article-title":"A subluxing arthropathy associated with the anti-Jo-1 antibody in polymyositis\/dermatomyositis","volume":"33","author":"Oddis","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2024.104453_bib0077","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s100670070030","article-title":"Clinical and serological aspects of patients with anti-Jo-1 antibodies\u2013an evolving spectrum of disease manifestations","volume":"19","author":"Schmidt","year":"2000","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.nmd.2024.104453_bib0078","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/rheumatology\/keu404","article-title":"Seronegative polyarthritis revealing antisynthetase syndrome: a multicentre study of 40 patients","volume":"54","author":"Lef\u00e8vre","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nmd.2024.104453_bib0079","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s10067-019-04471-y","article-title":"Sonographic findings from inflammatory arthritis due to antisynthetase syndrome","volume":"38","author":"Miller","year":"2019","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.nmd.2024.104453_bib0080","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/rheumatology\/ket453","article-title":"Distinct arthropathies of the hands in patients with anti-aminoacyl tRNA synthetase antibodies: usefulness of autoantibody profiles in classifying patients","volume":"53","author":"Kaneko","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nmd.2024.104453_bib0081","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2024.104453_bib0082","first-page":"44","article-title":"Timing of onset affects arthritis presentation pattern in antisyntethase syndrome","volume":"36","author":"Gonz\u00e1lez-Gay","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.nmd.2024.104453_bib0083","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.1097\/MD.0000000000000523","article-title":"In antisynthetase syndrome, ACPA are associated with severe and erosive arthritis: an overlapping rheumatoid arthritis and antisynthetase syndrome","volume":"94","author":"Meyer","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.nmd.2024.104453_bib0084","doi-asserted-by":"crossref","first-page":"e1144","DOI":"10.1097\/MD.0000000000001144","article-title":"Clinical spectrum time course in anti jo-1 positive Antisynthetase syndrome: results from an international retrospective multicenter study","volume":"94","author":"Cavagna","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.nmd.2024.104453_bib0085","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.3899\/jrheum.091402","article-title":"Anticyclic citrullinated peptide antibodies as markers of erosive arthritis in antisynthetase syndrome","volume":"37","author":"Cavagna","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.nmd.2024.104453_bib0086","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.autrev.2017.01.008","article-title":"Clinical follow-up predictors of disease pattern change in anti-Jo1 positive anti-synthetase syndrome: results from a multicenter, international and retrospective study","volume":"16","author":"Bartoloni","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.nmd.2024.104453_bib0087","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s12016-016-8528-9","article-title":"Serum Jo-1 Autoantibody and Isolated Arthritis in the Antisynthetase Syndrome: review of the Literature and Report of the Experience of AENEAS Collaborative Group","volume":"52","author":"Cavagna","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.nmd.2024.104453_bib0088","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/RHU.0000000000001234","article-title":"Anti-Jo-1 Syndrome Often Misdiagnosed as Rheumatoid Arthritis (for Many Years): a Single-Center Experience","volume":"27","author":"Kumar","year":"2021","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.nmd.2024.104453_bib0089","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.reuma.2019.10.001","article-title":"Autoantibodies to extractable nuclear antigens (ENAs) pattern in rheumatoid arthritis patients: relevance and clinical implications","volume":"17","author":"Emad","year":"2021","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"10.1016\/j.nmd.2024.104453_bib0090","doi-asserted-by":"crossref","first-page":"26","DOI":"10.5606\/ArchRheumatol.2018.6401","article-title":"The association of anti-aminoacyl-transfer ribonucleic acid synthetase antibodies in patients with rheumatoid arthritis and interstitial lung disease","volume":"33","author":"Matsushita","year":"2018","journal-title":"Arch Rheumatol"},{"key":"10.1016\/j.nmd.2024.104453_bib0091","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1136\/annrheumdis-2017-211401","volume":"76","author":"Rider","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nmd.2024.104453_bib0092","first-page":"S65","article-title":"The development of the disease activity score (DAS) and the disease activity score using 28 joint counts (DAS28)","volume":"32","author":"van Riel","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.nmd.2024.104453_bib0093","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/RHU.0b013e3181f3bf9c","article-title":"Antisynthetase syndrome presenting as rheumatoid-like polyarthritis","volume":"16","author":"Mumm","year":"2010","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.nmd.2024.104453_bib0094","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0133702","article-title":"Efficacy of rituximab in refractory inflammatory myopathies associated with anti- synthetase auto-antibodies: an open-label, Phase II Trial","volume":"10","author":"Allenbach","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.nmd.2024.104453_bib0095","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1093\/rheumatology\/keu024","article-title":"Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population","volume":"53","author":"Unger","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nmd.2024.104453_bib0096","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/rheumatology\/kew296","article-title":"The successful use of tocilizumab as third-line biologic therapy in a case of refractory anti-synthetase syndrome","volume":"55","author":"Murphy","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nmd.2024.104453_bib0097","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jbspin.2015.03.016","article-title":"Antisynthetase syndrome treated with tocilizumab","volume":"83","author":"Beaumel","year":"2016","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.nmd.2024.104453_bib0098","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1136\/annrheumdis-2017-211751","article-title":"Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial","volume":"77","author":"Tj\u00e4rnlund","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nmd.2024.104453_bib0099","doi-asserted-by":"crossref","first-page":"e01129","DOI":"10.1002\/rcr2.1129","article-title":"Successful baricitinib treatment of refractory anti-synthetase syndrome associated with interstitial lung disease","volume":"11","author":"Sugino","year":"2023","journal-title":"Respirol Case Rep"},{"key":"10.1016\/j.nmd.2024.104453_bib0100","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1093\/rheumatology\/keg388","article-title":"Polymyositis associated with infliximab treatment for rheumatoid arthritis","volume":"42","author":"Musial","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nmd.2024.104453_bib0101","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3109\/s10165-006-0523-1","article-title":"Polymyositis associated with infliximab treatment for rheumatoid arthritis","volume":"16","author":"Urata","year":"2006","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.nmd.2024.104453_bib0102","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.rbr.2015.12.005","article-title":"Three cases of anti-TNF induced myositis and literature review","volume":"57","author":"Zengin","year":"2017","journal-title":"Rev Bras Reumatol Engl Ed"},{"key":"10.1016\/j.nmd.2024.104453_bib0103","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10067-010-1666-1","article-title":"A case of antisynthetase syndrome in a rheumatoid arthritis patient with anti-PL-12 antibody following treatment with etanercept","volume":"30","author":"Ishikawa","year":"2011","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.nmd.2024.104453_bib0104","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s10067-009-1370-1","article-title":"Etanercept-induced anti-Jo-1-antibody-positive polymyositis in a patient with rheumatoid arthritis: a case report and review of the literature","volume":"29","author":"Ishikawa","year":"2010","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.nmd.2024.104453_bib0105","first-page":"240","article-title":"[Antisynthetase (anti PL-7 antibody) syndrome presenting as a skin rash and exacerbation of interstitial pneumonia during treatment for rheumatoid arthritis]","volume":"48","author":"Ishiguro","year":"2010","journal-title":"Nihon Kokyuki Gakkai Zasshi"},{"key":"10.1016\/j.nmd.2024.104453_bib0106","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1136\/ard.2007.077974","article-title":"A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies","volume":"67","author":"Dastmalchi","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nmd.2024.104453_bib0107","doi-asserted-by":"crossref","first-page":"577","DOI":"10.7326\/0003-4819-91-4-577","article-title":"A cutaneous lesion associated with myositis","volume":"91","author":"Stahl","year":"1979","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.nmd.2024.104453_bib0108","doi-asserted-by":"crossref","first-page":"e332","DOI":"10.1093\/rheumatology\/kead274","article-title":"Mechanic's hands are associated with interstitial lung disease in myositis patients regardless of the presence of antisynthetase antibodies","volume":"62","author":"Bandeira","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nmd.2024.104453_bib0109","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1111\/1756-185X.14428","article-title":"A prognostic analysis of antisynthetase syndrome-related interstitial lung disease","volume":"25","author":"Li","year":"2022","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.nmd.2024.104453_bib0110","first-page":"kead481","article-title":"Comparison of clinical features between patients with anti-synthetase syndrome and dermatomyositis: results from the MYONET registry","author":"Hum","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nmd.2024.104453_bib0111","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/rheumatology\/kex021","article-title":"A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies","volume":"56","author":"Pinal-Fernandez","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nmd.2024.104453_bib0112","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/1346-8138.15049","article-title":"Clinical manifestations of skin, lung and muscle diseases in dermatomyositis positive for anti-aminoacyl tRNA synthetase antibodies","volume":"46","author":"Fukamatsu","year":"2019","journal-title":"J Dermatol"},{"key":"10.1016\/j.nmd.2024.104453_bib0113","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1001\/jamadermatol.2019.1668","article-title":"Distinct histopathologic patterns of finger eruptions in dermatomyositis based on myositis-specific autoantibody profiles","volume":"155","author":"Okiyama","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.nmd.2024.104453_bib0114","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/art.42050","article-title":"Identification of Similarities Between Skin Lesions in Patients With Antisynthetase Syndrome and Skin Lesions in Patients With Dermatomyositis by Highly Multiplexed Imaging Mass Cytometry","volume":"74","author":"Patel","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.nmd.2024.104453_bib0115","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/annrheumdis-2017-211868","article-title":"The EuroMyositis registry: an international collaborative tool to facilitate myositis research","volume":"77","author":"Lilleker","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nmd.2024.104453_bib0116","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.3899\/jrheum.220989","article-title":"Myocarditis in patients with idiopathic inflammatory myopathies: clinical presentation and outcomes","volume":"50","author":"Chung","year":"2023","journal-title":"J Rheumatol"},{"key":"10.1016\/j.nmd.2024.104453_bib0117","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1161\/CIRCULATIONAHA.115.017430","article-title":"Global Myocardial Edema in Antisynthetase Syndrome Detected by Cardiovascular Magnetic Resonance Mapping Techniques","volume":"133","author":"Sado","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.nmd.2024.104453_bib0118","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.cardfail.2014.07.012","article-title":"Brief report: antisynthetase syndrome-associated myocarditis","volume":"20","author":"Sharma","year":"2014","journal-title":"J Card Fail"},{"key":"10.1016\/j.nmd.2024.104453_bib0119","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1097\/BOR.0000000000000753","article-title":"Cardiac involvement in inflammatory myopathies and inherited muscle diseases","volume":"32","author":"Lilleker","year":"2020","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.nmd.2024.104453_bib0120","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1016\/j.jacc.2018.09.072","article-title":"Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: expert Recommendations","volume":"72","author":"Ferreira","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.nmd.2024.104453_bib0121","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1183\/09031936.00156312","article-title":"Pulmonary hypertension in antisynthetase syndrome: prevalence, aetiology and survival","volume":"42","author":"Hervier","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.nmd.2024.104453_bib0122","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1136\/annrheumdis-2017-211174","article-title":"Infections and respiratory tract disease as risk factors for idiopathic inflammatory myopathies: a population-based case-control study","volume":"76","author":"Svensson","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nmd.2024.104453_bib0123","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1136\/annrheumdis-2011-200182","article-title":"Interaction of HLA-DRB1\u00d703 and smoking for the development of anti-Jo-1 antibodies in adult idiopathic inflammatory myopathies: a European-wide case study","volume":"71","author":"Chinoy","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nmd.2024.104453_bib0124","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1084\/jem.20041367","article-title":"Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy","volume":"201","author":"Casciola-Rosen","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.nmd.2024.104453_bib0125","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1002\/art.22790","article-title":"Novel conformation of histidyl-transfer RNA synthetase in the lung: the target tissue in Jo-1 autoantibody-associated myositis","volume":"56","author":"Levine","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2024.104453_bib0126","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1084\/jem.20020186","article-title":"Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells","volume":"196","author":"Howard","year":"2002","journal-title":"J Exp Med"},{"key":"10.1016\/j.nmd.2024.104453_bib0127","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13075-022-02745-6","article-title":"Longitudinal assessment of reactivity and affinity profile of anti-Jo1 autoantibodies to distinct HisRS domains and a splice variant in a cohort of patients with myositis and anti-synthetase syndrome","volume":"24","author":"Notarnicola","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.nmd.2024.104453_bib0128","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/art.41075","article-title":"Proinflammatory Histidyl-Transfer RNA Synthetase-Specific CD4+ T cells in the blood and lungs of patients with idiopathic inflammatory myopathies","volume":"72","author":"Galindo-Feria","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.nmd.2024.104453_bib0129","doi-asserted-by":"crossref","first-page":"260","DOI":"10.55563\/clinexprheumatol\/ohsmuj","article-title":"Alterations of peripheral blood B cell subsets in Chinese patients with adult idiopathic inflammatory myopathies","volume":"40","author":"Wang","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.nmd.2024.104453_bib0130","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.756018","article-title":"High-dimensional analysis reveals distinct endotypes in patients with idiopathic inflammatory myopathies","volume":"13","author":"Wilfong","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.nmd.2024.104453_bib0131","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jneuroim.2019.04.014","article-title":"Mass cytometry reveals an impairment of B cell homeostasis in anti-synthetase syndrome","volume":"332","author":"Dzangu\u00e9-Tchoupou","year":"2019","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.nmd.2024.104453_bib0132","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13075-020-02412-8","article-title":"Jo-1 autoantigen-specific B cells are skewed towards distinct functional B cell subsets in anti-synthetase syndrome patients","volume":"23","author":"Young-Glazer","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.nmd.2024.104453_bib0133","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa2117912","article-title":"Trial of Intravenous Immune Globulin in Dermatomyositis","volume":"387","author":"Aggarwal","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2024.104453_bib0134","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/acr2.11521","article-title":"Transcriptome Profiling of Immune Cell Types in Peripheral Blood Reveals Common and Specific Pathways Involved in the Pathogenesis of Myositis-Specific Antibody-Positive Inflammatory Myopathies","volume":"5","author":"Sugimori","year":"2023","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.nmd.2024.104453_bib0135","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1051609","article-title":"Efficacy and safety of rituximab treatment in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis","volume":"13","author":"Zhen","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.nmd.2024.104453_bib0136","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3899\/jrheum.120555","article-title":"BAFF expression correlates with idiopathic inflammatory myopathy disease activity measures and autoantibodies","volume":"40","author":"L\u00f3pez De Padilla","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.nmd.2024.104453_bib0137","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.coi.2021.06.012","article-title":"Keeping up with the stress of antibody production: BAFF and APRIL maintain memory plasma cells","volume":"71","author":"Cornelis","year":"2021","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.nmd.2024.104453_bib0138","first-page":"kead281","article-title":"Belimumab treatment of adult idiopathic inflammatory myopathy","author":"Marder","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nmd.2024.104453_bib0139","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/rheumatology\/keac602","article-title":"B-cell receptor profiling before and after IVIG monotherapy in newly diagnosed idiopathic inflammatory myopathies","volume":"62","author":"Anang","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nmd.2024.104453_bib0140","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.3390\/cells12172198","article-title":"Identification of Unique microRNA Profiles in different types of idiopathic inflammatory myopathy","volume":"12","author":"Mu\u00f1oz-Braceras","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.nmd.2024.104453_bib0141","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ejphar.2015.03.048","article-title":"Regulatory acceptance of animal models of disease to support clinical trials of medicines and advanced therapy medicinal products","volume":"759","author":"Cavagnaro","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.nmd.2024.104453_bib0142","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/25785826.2022.2137968","article-title":"Murine models of idiopathic inflammatory myopathy","volume":"46","author":"Konishi","year":"2023","journal-title":"Immunol Med"},{"key":"10.1016\/j.nmd.2024.104453_bib0143","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/art.30113","article-title":"Role of innate immunity in a murine model of histidyl-transfer RNA synthetase (Jo-1)-mediated myositis","volume":"63","author":"Soejima","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2024.104453_bib0144","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2020.101503","article-title":"Clinical manifestations and treatment of antisynthetase syndrome","volume":"34","author":"Marco","year":"2020","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.nmd.2024.104453_bib0145","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3109\/s10165-007-0553-3","article-title":"Step-up versus primary intensive approach to the treatment of interstitial pneumonia associated with dermatomyositis\/polymyositis: a retrospective study","volume":"17","author":"Takada","year":"2007","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.nmd.2024.104453_bib0146","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s10067-017-3854-8","article-title":"Risk factors for the recurrence of interstitial lung disease in patients with polymyositis and dermatomyositis: a retrospective cohort study","volume":"37","author":"Nakazawa","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.nmd.2024.104453_bib0147","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.rmed.2013.02.015","article-title":"A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis\/dermatomyositis","volume":"107","author":"IC","year":"2013","journal-title":"Respir Med"},{"key":"10.1016\/j.nmd.2024.104453_bib0148","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.chest.2019.05.023","article-title":"Long-term treatment with azathioprine and mycophenolate mofetil for myositis-related interstitial lung disease","volume":"156","author":"Huapaya","year":"2019","journal-title":"Chest"},{"key":"10.1016\/j.nmd.2024.104453_bib0149","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11926-018-0731-7","article-title":"Management of interstitial lung disease in patients with myositis specific autoantibodies","volume":"20","author":"Mecoli","year":"2018","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.nmd.2024.104453_bib0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2023.152164","article-title":"Intravenous cyclophosphamide improves functional outcomes in interstitial lung disease related to idiopathic inflammatory myopathies","volume":"59","author":"Moreno-Torres","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.nmd.2024.104453_bib0151","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/01.md.0000173991.74008.b0","article-title":"Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients","volume":"84","author":"Troyanov","year":"2005","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.nmd.2024.104453_bib0152","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1055\/s-0044-1785536","article-title":"Review of pulmonary manifestations in antisynthetase syndrome","volume":"45","author":"Ghanbar","year":"2024","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.nmd.2024.104453_bib0153","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3899\/jrheum.180778","article-title":"Efficacy of glucocorticoids and calcineurin inhibitors for anti-aminoacyl-tRNA Synthetase Antibody-positive Polymyositis\/dermatomyositis-associated interstitial lung disease: a propensity score-matched analysis","volume":"46","author":"Hozumi","year":"2019","journal-title":"J Rheumatol"},{"key":"10.1016\/j.nmd.2024.104453_bib0154","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00296-015-3328-8","article-title":"Survival benefit associated with early cyclosporine treatment for dermatomyositis-associated interstitial lung disease","volume":"36","author":"Go","year":"2016","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.nmd.2024.104453_bib0155","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00408-009-9146-6","article-title":"Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis\/dermatomyositis","volume":"187","author":"Suzuki","year":"2009","journal-title":"Lung"},{"key":"10.1016\/j.nmd.2024.104453_bib0156","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1183\/09031936.00163911","article-title":"Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy","volume":"40","author":"Keir","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.nmd.2024.104453_bib0157","series-title":"Rituximab compared to intravenous cyclophosphamide in adults with connective tissue disease-associated interstitial lung disease: the recital rct","author":"Maher","year":"2024"},{"key":"10.1016\/j.nmd.2024.104453_bib0158","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2024.104453_bib0159","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2024.104453_bib0160","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S2213-2600(20)30036-9","article-title":"Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial","volume":"8","author":"Wells","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.nmd.2024.104453_bib0161","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/1753465816686743","article-title":"Optimizing quality of life in patients with idiopathic pulmonary fibrosis","volume":"11","author":"van Manen","year":"2017","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.nmd.2024.104453_bib0162","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1111\/ajt.17177","article-title":"Lung transplantation for interstitial lung disease in idiopathic inflammatory myositis: a cohort study","volume":"22","author":"Rivi\u00e8re","year":"2022","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nmd.2024.104453_bib0163","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.866087","article-title":"Aminoacyl-tRNA synthetases: on Anti-synthetase syndrome and beyond","volume":"13","author":"Galindo-Feria","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.nmd.2024.104453_bib0164","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/art.38270","article-title":"Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis","volume":"66","author":"Aggarwal","year":"2014","journal-title":"Arthritis & Rheumatology (Hoboken, NJ)"},{"key":"10.1016\/j.nmd.2024.104453_bib0165","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kew275","article-title":"Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab","author":"Aggarwal","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nmd.2024.104453_bib0166","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1111\/ajt.12220","article-title":"A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function","volume":"13","author":"Kamburova","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nmd.2024.104453_bib0167","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/art.22400","article-title":"Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis","volume":"56","author":"Vos","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2024.104453_bib0168","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric Antigen Receptor Therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2024.104453_bib0169","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(23)00023-5","article-title":"CD19-targeted CAR T cells in refractory antisynthetase syndrome","volume":"401","author":"M\u00fcller","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.nmd.2024.104453_bib0170","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1093\/rheumatology\/kead330","article-title":"Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T cells after failure of several B-cell depleting antibodies","volume":"63","author":"Taubmann","year":"2024","journal-title":"Rheumatology"},{"key":"10.1016\/j.nmd.2024.104453_bib0171","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1001\/jama.2023.8753","article-title":"CD19-Targeting CAR T Cells for myositis and interstitial lung disease associated with antisynthetase syndrome","volume":"329","author":"Pecher","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.nmd.2024.104453_bib0175","series-title":"239th ENMC International Workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14-16 December 2018","first-page":"70","article-title":"ENMC 239th Workshop Study Group","volume":"30","author":"Mammen","year":"2020"},{"key":"10.1016\/j.nmd.2024.104453_bib0172","first-page":"S118","volume":"63 Suppl 11","author":"Rider","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.nmd.2024.104453_bib0173","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/nrrheum.2018.33","article-title":"Update on outcome assessment in myositis","volume":"14","author":"Rider","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.nmd.2024.104453_bib0174","series-title":"213th ENMC International Workshop: Outcome measures and clinical trial readiness in idiopathic inflammatory myopathies, Heemskerk, The Netherlands, 18\u201320 September 2015","volume":"0","author":"Benveniste","year":"2016"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896624009490?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896624009490?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T17:16:23Z","timestamp":1734023783000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896624009490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":175,"alternative-id":["S0960896624009490"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2024.104453","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"273rd ENMC International workshop: Clinico-Sero-morphological classification of the Antisynthetase syndrome. Amsterdam, The Netherlands, 27-29 October 2023","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2024.104453","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}],"article-number":"104453"}}